Clinical Trials
4 trialsNCT00085449 2019-11-27
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT00129753 2018-11-08
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00081068 2013-01-08
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00226512 2011-04-08
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Hadassah Medical Organization
Phase 3 Withdrawn